Infigratinib, an FGFR1-3 inhibitor that was approved by the FDA in May 2021 as second line for advanced cholangiocarcinoma with FGFR2 fusion genes but later revoked in 2024, has been tested for locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with FGFR2 gene amplification in the LB1001-201 trial (NCT05019794), a single-arm phase II trial with two cohorts, with an ORR of 25% and a disease control rate (DCR) of 80%, with 15 out of 19 patients presenting tumor shrinkage, the maximum from baseline being a reduction of 78.5% [74,75]. The gene discussed is FGFR2; the disease is neoplasm.